BORDEAUX, France: Tooth extraction is the most common procedure performed in oral surgery.1 For example, ten million third molars are removed each year in the US alone, according to the American Public Health Association.2 Dentists are ethically committed to using the least traumatic surgical options and least invasive techniques in order to ensure patients’ well-being, thus less traumatic extraction and implant placement are becoming the norm in today’s implant surgery.
BORDEAUX, France: Michael Rynerson is the new CEO of the dental and medical technology and device manufacturer ACTEON, which is headquartered in France. The supervisory board of Finapolline, the holding company of ACTEON, appointed him to the position effective on 1 June. The chairman of the supervisory board commented that Rynerson has over 25 years of experience, most notably in the dental industry, and possesses the skills to lead the company out of the current health and economic crisis and through its next phase of development.
CHICAGO, U.S.: Few products have had such a positive effect on dentistry as the EXPASYL gingival retraction paste from ACTEON. After 20 years of clinical research and efficacy, EXPASYL continues to be the choice of many dentists for tissue management during restorative and cosmetic dental treatment. Now, EXPASYL EXACT is available on the market. It offers the same results in the exact amount needed in a cost-effective, single-use capsule that can be used in any composite gun. This means that there will be no more wasted material and there is no need to purchase expensive application guns. At the 155th Chicago Dental Society Midwinter Meeting currently being held in Chicago, interested parties can view the new product at the ACTEON booth (#2811).